Cevimeline

Cholinergic Receptor Agonist — NERVOUS SYSTEM

Key facts

Cevimeline is an ofp drug in the Cholinergic Receptor Agonist class catalogued in DrugCentral. It was first approved by the FDA in 2000. Its mechanism of action is classified as Cholinergic Muscarinic Agonists. DrugCentral lists 5 molecular targets, including CHRM1, CHRM3 and CHRM5. Recorded indications include Xerostomia Secondary to Sjogren's Syndrome.

• Approval status: ofp (first approved 2000 by the FDA).
• Drug class: Cholinergic Receptor Agonist.
• Mechanism of action: Cholinergic Muscarinic Agonists.
• Molecular targets: CHRM1, CHRM3, CHRM5 and CHRM2 (5 listed in DrugCentral).
• Indications: Xerostomia Secondary to Sjogren's Syndrome.
• ATC code: N07AX03 (Other parasympathomimetics).
• Molecular formula: C10H17NOS; molecular weight 199.32 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Xerostomia Secondary to Sjogren's Syndrome

Contraindications (20)

• Acute exacerbation of asthma
• Angina pectoris
• Angle-closure glaucoma
• Asthma
• Breastfeeding (mother)
• Calculus in biliary tract
• Cholangitis
• Cholecystitis
• Chronic bronchitis
• Conduction disorder of the heart
• Exacerbation of asthma
• Iritis
• Kidney stone
• Myocardial infarction
• Night blindness
• Non-Q wave myocardial infarction
• Reduced visual acuity
• Renal colic
• Severe chronic obstructive pulmonary disease
• Ureteral Spasm

Mechanism & targets

• Mechanism of action (MoA): Cholinergic Muscarinic Agonists
• Established pharmacologic class: Cholinergic Receptor Agonist

Molecular targets (5)

Target	Gene	Action	Activity
Muscarinic acetylcholine receptor M1	CHRM1	agonist	EC50 7.64
Muscarinic acetylcholine receptor M3	CHRM3	agonist	EC50 7.32
Muscarinic acetylcholine receptor M5	CHRM5	unknown	EC50 7.20
Muscarinic acetylcholine receptor M2	CHRM2	unknown	EC50 5.98
Muscarinic acetylcholine receptor M4	CHRM4	unknown	EC50 5.88

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
2000-01-11	FDA	—	DAIICHI SANKYO

ATC classification

ATC code	Therapeutic hierarchy
N07AX03	NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › PARASYMPATHOMIMETICS › Other parasympathomimetics

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• FDA label: CYP2D6 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Headache	30.6
Dry eye	29.5
Dry mouth	26.6
Product dose omission issue	20.1

Chemical structure

• Molecular formula: C₁₀H₁₇NOS
• Molecular weight: 199.32 g/mol
• CAS number: —
• InChIKey: WUTYZMFRCNBCHQ-UHFFFAOYSA-N
• PubChem CID: 25137844

CC1OC2(CS1)CN1CCC2CC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Cevimeline used for?

DrugCentral lists the following indications for Cevimeline: Xerostomia Secondary to Sjogren's Syndrome.

How does Cevimeline work?

Cevimeline is classified as Cholinergic Muscarinic Agonists; its molecular targets in DrugCentral include CHRM1 (agonist), CHRM3 (agonist), CHRM5 and CHRM2.

When was Cevimeline first approved?

Cevimeline was first approved by the FDA in 2000.

What drug class does Cevimeline belong to?

Cevimeline is in the Cholinergic Receptor Agonist class.

What is the chemical formula of Cevimeline?

Cevimeline has the molecular formula C10H17NOS and a molecular weight of 199.32 g/mol.

Sources

• DrugCentral drug card 584 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL168815 — compound record and bioactivity
• PubChem CID 25137844 — chemical identifiers
• DrugBank DB00185 — drug record
• FDA UNII K9V0CDQ56E — substance identity
• DailyMed: FDA labels for Cevimeline — current prescribing information (label search)
• UniProt P11229 (CHRM1) — target protein
• UniProt P20309 (CHRM3) — target protein
• UniProt P08912 (CHRM5) — target protein
• UniProt P08172 (CHRM2) — target protein
• UniProt P08173 (CHRM4) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.